As a source of hope, an EGFR TKI has appeared in the realm of cancer treatments aimed at specific cells for patients with advanced-stage NSCLC (NSCLC).A potent TKI (TKI), an EGFR TKI, has markedly changed the forecast of recovery for patients with EGFR mutated NSCLC, leading to a prolonged mean time to progression (average time without progression time).This article explores the significance of an EGFR TKI's average time without progression time and its ramifications for patient care, in addition to continuing research focused on improving treatment effectiveness.A next generation EGFR…
